Rivaroxaban API Market
Rivaroxaban API Market Scope: Industry Analysis,
Market Size, Growth, Trends Till 2031
Request Sample Report
Rivaroxaban API Market Size and Growth
The Rivaroxaban API market is projected to grow significantly, driven by increasing demand for anticoagulants and rising incidences of thromboembolic disorders. The market size was valued at approximately $500 million in 2023, with expectations of reaching over $800 million by 2030, highlighting robust compound annual growth throughout the forecast period.
Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Piramal Enterprises Limited
◍ Dr. Reddy's Laboratories
◍ Polpharma S. A.
◍ ZCL Chemicals Limited
◍ Interquim SA
◍ Medichem S.A
◍ UQUIFA
◍ Inke
◍ Tecoland
◍ Teva Pharmaceutical Industries Ltd.
◍ Symed Labs Limited
◍ Unichem Laboratories Limited
◍ Lupin Ltd
◍ Neuland Laboratories
◍ NG ZIP CHEMICAL INDUSTRIAL
◍ Zhejiang Huahai Pharmaceutial. Co., Ltd.
◍ Glenmark Pharmaceuticals
◍ Srini Pharmaceuticals
The Rivaroxaban API market is competitive, driven by companies like Piramal Enterprises, Dr. Reddy's, and Teva, focusing on production and distribution. They enhance market growth via innovation and strategic partnerships. Sales figures include Teva's revenue of $16 billion and Dr. Reddy’s at $2.2 billion, showcasing their market influence. Request Sample Report
Limited
Market Segmentation
By Application
Rivaroxaban Tablets
Others
By Product
◍ Purity≥98%
Purity<98%
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
